Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?

Merck (MRK) reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings of $2.22 per share rose 12$15.53 billion rose 1% year over year as higher sales of blockbuster cancer drug, Keytruda, new products like Welireg, Winrevair and Capvaxive and strong performance of the Animal Health segment were partially offset by lower sales of the HPV vaccine Gardasil in China. Keytruda, the biggest p ...